Drug intelligence / Profile preview

Jinlianhua lozenge

Development stage: Unknown
Lead developer: Jilin Aodong Pharmaceutical Group
Administration: Oral

Overview

Jinlianhua lozenge is a traditional Chinese medicine (TCM) product developed by Jilin Aodong Yanbian Pharmaceutical Co., Ltd. for the treatment of acute pharyngitis and acute catarrhal tonsillitis. The formulation is based on the extract of *Trollius chinensis* Bunge (Jinlianhua), a plant traditionally used in China for its anti-inflammatory, antibacterial, and heat-clearing properties. It is specifically indicated for patients presenting with the wind-heat pattern of TCM. The drug has been evaluated in Phase II clinical trials in China, where its efficacy and safety were compared against Jinlianhua oral solution to provide a localized delivery method for soothing throat inflammation and reducing symptoms.

Brand names: Jinlianhua lozenge
Other names: Jinlianhua hanpian

Beyond the preview

Go deeper on Jinlianhua lozenge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinlianhua lozenge.

Explore the full profile